本文選題：急性白血病 + 微小殘留病��； 參考：《中國實驗血液學雜志》2017年03期

【摘要】：目的:研究非清髓造血干細胞移植(NST)前后采用流式細胞術(FCM)動態(tài)監(jiān)測微小殘留病(MRD),以預測移植后急性白血病(AL)復發(fā)的意義,為臨床早期干預提供指導。方法:回顧性研究2011年1月至2015年12月在軍事醫(yī)學科學院附屬醫(yī)院血液科行NST的成人AL患者51例,對所有患者移植前骨髓形態(tài)學完全緩解(CR)期內,移植前35 d內、移植后1、2、3月內,以后每3月至移植后2年、2年后每6個月內采集骨髓監(jiān)測MRD。低水平MRD組(A組)共33例(移植后每次檢測MRD0.2%),高水平MRD組(B組)共18例(移植后動態(tài)監(jiān)測MRD,至少1次≥0.2%)。結果:移植后2組2年累計復發(fā)率分別為6.1%和50%(P=0.001)。多因素分析表明:移植后M RD≥0.2%是AL移植后復發(fā)的獨立的高危因素,高水平MRD組復發(fā)風險是低水平MRD組的5.84倍(P=0.036)。移植后復發(fā)組與未復發(fā)組的死亡率分別為81.8%和46.3%(P=0.036)。結論:非清髓異基因造血干細胞移植治療急性白血病中,采用FCM動態(tài)監(jiān)測MRD是預測移植后早期復發(fā)的重要方法,移植后MRD≥0.2%可作為白血病早期復發(fā)的預警,以及指導臨床早期給予干預措施的重要依據(jù)。
[Abstract]:Objective: to study the dynamic monitoring of MRDV by flow cytometry (FCM) before and after non-myeloablative hematopoietic stem cell transplantation (NST) in order to predict the recurrence of acute leukemia (ALL) after transplantation and to provide guidance for early clinical intervention. Methods: a retrospective study of 51 adult AL patients who were treated with NST from January 2011 to December 2015 in Hematology Department of affiliated Hospital of the Academy of military Medical Sciences was conducted. The bone marrow morphology of all the patients was completely relieved before transplantation and 35 days before transplantation. Bone marrow monitoring MRDs were collected within 1 ~ 2 months, 3 months, 3 months, 2 years and 2 years after transplantation. There were 33 cases in low level MRD group (MRD 0. 2% after transplantation and 18 cases in high level MRD group B) (dynamic monitoring of MRD after transplantation, 鈮，

本文編號：1865689